Drug Profile
AVI 4126
Alternative Names: AVI-4126; Oncomyc-NG; Resten-MP; Resten-NGLatest Information Update: 13 Jul 2012
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Developer Sarepta Therapeutics
- Class Antineoplastics; Ischaemic heart disorder therapies; Morpholines; Urologics
- Mechanism of Action Proto-oncogene protein c-myc modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Polycystic kidney disease
- Discontinued Cancer; Coronary artery restenosis; Coronary disorders
Most Recent Events
- 13 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
- 12 Jul 2012 Discontinued - Phase-I for Coronary artery restenosis in USA (PO)
- 12 Jul 2012 Discontinued - Phase-I for Coronary disorders in Europe (Intracoronary)